Adamed wins the Spanish title of “R&D leader in the pharmaceutical and biotechnology sectors”

The idea behind the competition is to highlight Madrid’s unique potential as a city with a thriving entrepreneurial spirit. The award winners include companies and businesses from various industry sectors: technology, food, construction, education or healthcare. The group comprises both private businesses and public entities which contribute to the growth of investment capacity and increase the GDP of the whole country. All the award-winning organizations have their headquarters or offices and facilities in the region. The 25 winners also share the ability to adapt to the new digital reality and develop future-proof technological solutions.

The gala, hosted by María Eugenia Carballedo, President of the Assembly of Madrid, took place on 2 March 2022. The award was accepted on behalf of AdamedLaboratorios, Adamed Pharma’s Spanish branch company, by the CEO Marcin Nowak.

“The company’s main goals are to find new, effective and safe therapies for patients around the world, and to promote innovation as a strategic asset. Our mission is to respond to the key challenges of modern medicine. We work in the present with an eye to the future. This is particularly important today, in the context of difficulties and challenges we have had to face in recent years” – Marcin Nowak said when accepting the award.

Adamed Pharma S.A. has been present on the Spanish market through its representative office for over a decade. Today, AdamedLaboratorios has a team of more than 100 people, many of whom are responsible for the development of the newly launched cardiological line called Adamed Cardio. Between 2022 and 2025, the company is planning to launch a total of 16 new products to the Spanish market with a view to providing effective novel therapies for chronic cardiovascular conditions. Many of these products provide added value in the form of combination products containing more than one API, so that the number of tablets taken by patients can be reduced. The added value relates both to enhanced therapeutic efficacy and improved quality of patient life. The company’s ambition is to enter the top 50 pharmaceutical companies in the open Rx market in Spain over the next 5–7 years.

***

La Razón is a Spanish daily newspaper founded in 1998 in Madrid by Luis Maria Ansón. The newspaper has a country-wide circulation and local editions in Barcelona, Murcia, Seville, Valencia, and Valladolid. With a circulation of 142,838 copies, La Razón ranks fifth among Spain’s largest-circulation national daily newspapers (after ABC, El País, El Mundo, and Barcelona’s La Vanguardia).